Zoekresultaten - You searched for Stock Market

400 results

Biocartis Group NV: Disclosure of outstanding voting securities

Read more

Biocartis Group NV: Disclosure of outstanding voting securities

Read more

Academia-Industry Connect Meeting: Knowledge Valorisation: Matching science and market needs

Read more

Bone Therapeutics Launches Equity Placement

Read more

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease

Read more

Acacia Pharma announces its intention to launch an initial global offering and to list its shares on Euronext Brussels

Read more

Biocartis announces 2017 results and 2018 outlook

Read more

Bone Therapeutics announces private placement of convertible bonds

Read more

Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement

Read more

Update on mithra and mayne pharma’s vaginal contraceptive ring opportunity

Read more

Mithra Obtains First Marketing Authorization for Myring™ in Europe

Read more

Biocartis Creates New Warrant Plan

Read more

Mithra signs exclusive license and supply agreement for vaginal contraceptive ring in Australia and New Zealand

Read more

Inbiose secures €4 million in debt financing

Read more

Market of 105 billion euros open to Flemish biotech companies

Read more

Mithra & Gynial sign commercialization agreement for MyringTM in Austria

Read more

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Read more

Mithra Submits Myring™ for European Marketing Approval

Read more

Ablynx announces launch of proposed global offering

Read more

Suspension of trading in Ablynx shares on Euronext Brussels

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law) (1)

Read more

Galapagos creates new warrant plan

Read more

argenx reports first quarter 2018 financial results and provides business update

Read more

flanders.bio Ghent becomes biotechnology capital of europe

Read more

argenx receives feedback from Japan's PMDA on Phase 3 clinical trial

Read more

argenx announces launch of proposed public offering in the United States

Read more

argenx reports third quarter 2018 financial results and provides business update

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

argenx announces launch of proposed initial public offering in the United States

Read more

Biocartis launches CE-marked IVD test for lung cancer

Read more

Aphea.Bio aims at leading position in next generation agricultural biologicals

Read more

Kempen & Co appoints Jan De Kerpel as Managing Director Life Sciences

Read more

Biocartis Group NV: Biocartis' Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements

Read more

Ablynx: publication in accordance with article 14 of the Belgian law regarding the publication of major shareholdings

Read more

Biocartis announces H1 2017 results

Read more

BioFIT 2017

Read more

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Read more

Mithra Announces Completion of Recruitment in Donesta® Phase II Study

Read more

ThromboGenics Business Update - Q3 2017

Read more

Mithra Completes Recruitment for Estelle® Phase III Study in US and Canada

Read more

ThromboGenics Strengthens Leadership Team

Read more

Bone Therapeutics Business Update for Third Quarter 2017

Read more

Biocartis Group NV: Idylla(TM) Performance Data Presented by US Key Opinion Leaders at Association for Molecular Pathology 2017 Conference

Read more

Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE

Read more

Mithra Announces Positive Outcome of Myring™ Commercial Batch Bioequivalence Study

Read more

MDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain

Read more

Mithra Announces 36-month Shelf Life Extension for Tibelia®

Read more

Publication of a Transparency Notification Received by Mithra Pharmaceuticals sa/nv

Read more

Biocartis successfully raises EUR 80 million in an equity placement

Read more

Mithra Provides Update on Estelle® and Donesta® Studies

Read more

Biocartis and Amgen Sign Companion Diagnostic Agreement for Idylla(TM) RAS Biomarker Tests

Read more

Mithra Announces Valorization of French Subsidiary

Read more

Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline

Read more

Mithra Finalizes Estelle® Contract with Brazilian Women’s Health Leader Libbs

Read more

Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

Read more

Mithra and Adamed Sign Commercialization Agreement for MyringTM in the Czech Republic

Read more

Biocartis - Disclosure of a transparency notification

Read more

Will 2018 be the year of biotech M&A? - An analysis by KBC Securities

Read more

UgenTec and MDxHealth sign partnership agreement for software to support interpretation of molecular test results

Read more

Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla(TM) platform

Read more

Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB®

Read more

Imec.istart is ranked fourth in UBI Global’s University Business Accelerator ranking

Read more

Disclosure of a transparency notification

Read more

MedFIT - Fostering Innovation in medTech

Read more

Mithra and Mayne Pharma’s Vaginal Contraceptive Ring Accepted for Filing by FDA

Read more

DuPont and Inbiose Celebrate EU Regulatory Approval of Their First Human Milk Oligosaccharide Ingredient for Infant Formula

Read more

Mithra signs principle agreement for commercialization of Estelle® in canada

Read more

Bone Therapeutics Reports Full Year 2017 Results

Read more

Biocartis Q1 2018 business update

Read more

Bone Therapeutics Strengthens Board with the Appointment of Claudia D’Augusta as Non-Executive Director

Read more

Agilent Technologies to Enhance Lab Informatics with Acquisition of Genohm

Read more

Bone Therapeutics Business Update for First Quarter 2018

Read more

Bone Therapeutics Information on the total number of voting rights and shares

Read more

ThromboGenics Business Update - Q1 2018

Read more

ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149

Read more

Bone Therapeutics: Information on the total number of voting rights and shares

Read more

Mithra launches capital increase by means of a private placement via an accelerated bookbuild offering

Read more

Mithra announces further positive phase IBB Donesta® efficacy and safety data

Read more

Mithra successfully raises eur 77.5 million

Read more

Mithra signs binding heads of terms for commercialization of Estelle® in South Korea with women's health specialist Hyundai Pharm

Read more

MDxHealth launch agreement with Philips for prognostic prostate cancer biomarker

Read more

Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

Read more

Mithra: Publication of a Transparency Notification Received from François Fornieri

Read more

Mithra and Mediner sign LSA for Tibelia® in Hungary

Read more

Biocartis launches innovative Idylla(TM) MSI Assay

Read more

Mithra announces belux agreement with ceres pharma worth over eur 40 million

Read more

Start with the end in Mind – Healthcare Market Access in the Digital Age

Read more

Biocartis and Wondfo Announce Joint Venture for Commercialization of Idylla(TM) Platform in China

Read more

ThromboGenics becomes "Oxurion"

Read more

Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study

Read more

Mithra signs exclusive license and supply agreement for commercialization of Tibelia® in Taiwan

Read more

Webinar commercializing on your own: panel discussion with insights from emerging biopharma executives

Read more

Mithra Finalizes Contract for the Commercialization of Estelle® with South Korean Women's Health Leader Hyundai Pharm

Read more

Mithra Announces 2018 Half Year Results

Read more

Mithra Signs Exclusive License And Supply Agreement For The Commercialization Of Myring™ In Chile With Laboratorio Pasteur

Read more

Mithra: 2018 update and 2019 outlook given at the cphi conference

Read more

Bone Therapeutics announces single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis

Read more

Mithra signs exclusive license and supply agreement with Adcock Ingram for commercialization of Estelle® in Southern Africa

Read more

Bone Therapeutics announces conclusions from interim analysis of Phase III PREOB study in hip osteonecrosis

Read more

Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle®

Read more

Mithra: full Estetrol (E4) program update provided at scientific advisory board meetings

Read more

BioBase4SME Natural Fibertastic Workshop aims to encourage SMEs to apply for fully funded Bio-Innovation Coupons for fibre application testing

Read more

Galapagos announces launch of proposed public offering

Read more

argenx files registration statement for a proposed public offering in the United States

Read more

Biocartis Group NV: Biocartis Q1 2017 Business Update

Read more

Biocartis Group NV: Biocartis announces its new CEO

Read more

Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

Read more

Mithra to Initiate PK Study for Estelle®

Read more

MDxHealth Shareholder Transparency Notification

Read more

Multiplicom launches complete CE-IVD marked solution in Europe for all BRCA testing needs

Read more

500 vacancies in the Flemish biotech sector

Read more

Galapagos creates new warrant plan

Read more

Mithra Receives GMP Approval for Myring™ Production

Read more

Biocartis Group NV: Biocartis launches CE-marked IVD NRAS test for colorectal cancer

Read more

Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors

Read more

Mithra Obtains Marketing Authorization for Tibelia® in France

Read more

Mithra Signs Exclusive Agreement for Tibelia® in Canada

Read more

ThromboGenics to Present the Industry Pipeline of DME Treatments

Read more

Biocartis Group NV: Disclosure of a transparency notification

Read more

Kiadis Pharma raises €5 million in private placement with institutional investors

Read more

Software as a Medical Device

Read more

Publication in accordance with article 14 of the law of May 2007 regarding the publication of major shareholdings (the "Transparency Law")

Read more

Swissmedic has accepted for review the file on Cx601 for the treatment of Crohn's disease patients

Read more

Mithra Successfully Raises €26.1 Million

Read more

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean

Read more

Bone Therapeutics Strengthens Board of Directors

Read more

UgenTec moves into PCR middleware, partners with Haman Laborautomation

Read more

Publication in accordance with art. 14 of the Belgian Law regarding the publication of major shareholdings (the "transparancy law")

Read more

Mithra Strengthens E4 Patent Position in Australian Market

Read more

Biocartis Group NV: Biocartis and A*STAR's ETPL initiate development of breast cancer assay to guide therapy selection

Read more

TiGenix: Transparency Information

Read more

Mithra: Recruitment Completed in Estelle® Population PK Substudy

Read more

UgenTec receives €50.000 grant by European Union

Read more

Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer

Read more

Biocartis Group NV: Strong performance data of proprietary MSI Biomarkers for the Idylla(TM) MSI Test to be published at ESMO

Read more

Mindbytes expands to North America to develop next generation serious medical games driven by artificial intelligence

Read more

Biocartis Group NV: Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

Read more

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

Read more

ThromboGenics Business Update - H1 2017

Read more

PharmaFluidics appoints Fasha Mahjoor as independent director

Read more

Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access

Read more

Bone Therapeutics reports strong interim results from ALLOB® Phase IIA spinal fusion study

Read more

ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

Read more

Bone Therapeutics announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis

Read more

Mithra announces 2017 half year results

Read more

Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB® in Japan

Read more

Mithra Signs Commercial Agreement With Brazilian Leader in Women’s Health Libbs for Estelle® in Brazil

Read more

Ablynx files registration statement for a proposed global offering

Read more

Ablynx - Publication in accordance with art.14 of the Belgian law of 2/05/2017 regarding the publication of major shareholdings (the "transparancy law")

Read more

Mithra’s Marketing Authorization Application for Tibelia® Accepted by Health Canada

Read more

Ablynx - Publication in accordance with art.14 of the Belgian Law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy law")

Read more

ONTOFORCE wins the EIT Venture Award 2017

Read more

TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601

Read more

Ablynx closes $200 Million Initial Public Offering in the United States

Read more

MDxhealth Enters into Distribution Agreement with Unilabs for SelectMDx for Prostate Cancer

Read more

Ablynx closes on underwriters' option to purchase $30 million of additional shares in the U.S. initial public offering

Read more

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Read more

MDxHealth Nine Month Trading Update

Read more

TiGenix strengthens European IP protection around lead development program Cx601

Read more

Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx - Correction of Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

Read more

Ablynx: publication regarding the publication of major shareholdings

Read more

Ablynx: publication regarding the publication of major shareholdings (the "transparancy law")

Read more

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

Read more

Ablynx announces results for the first nine months of 2017 and a year-to-date business update

Read more

Genohm: ISO 9001:2015 Certification - It’s a Big Deal

Read more

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

Read more

JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix

Read more

Ablynx - Publication in accordance with §14 of the Belgian Law

Read more

The Adecco Group Announces the Acquisition of CMAST

Read more

Galapagos to enter NASDAQ Biotech Index

Read more

Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries

Read more

New at Poulpharm: Animal facility for studies demanding high-containment levels

Read more

argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million

Read more

TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform

Read more

TiGenix Transparency notification pursuant to Article 14 of the Law of May 2, 2007

Read more

Ablynx announces board changes

Read more

PharmaFluidics raises 7.3 million euro to expand commercialization of novel micro-chip device for biomarker, diagnostics and drug development applications

Read more

TiGenix - Transparency Information

Read more

TiGenix - Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

Ablynx announces 2017 full year results

Read more

MDxHealth financial results

Read more

Rousselot innovation days 2018

Read more

MDxHealth contract SelectMDx with Roman Hospital

Read more

argenx reports fourth quarter business update and full year 2017 financial results

Read more

Life Sciences Baltics 2018

Read more

MDxHealth's New Share Capital Amount and New Number of Shares

Read more

MDxHealth Shareholder Transparency Declaration

Read more

UgenTec: announcing our $ 9.3 million Series A funding

Read more

TiGenix Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

Promethera Biosciences Announces Updates to its Board of Directors

Read more

argenx appoints Keith Woods as Chief Operating Officer

Read more

MDxHealth Shareholder Transparency Declaration

Read more

UgenTec Announces partnership with Serosep Ltd.

Read more

VIB presents its 2017 annual results and confirms its reputation as global player

Read more

MDxHealth (R): SelectMDx Included in Dutch DRG Reimbursement System

Read more

MDxHealth Provides First Quarter 2018 Business Update

Read more

Ardena acquires Syntagon and strengthens API offering

Read more

Sanofi and Ablynx announce the successful results of the initial tender offer period for ablynx and commencement of squeeze-out tender period

Read more

Promethera Biosciences Establishes Branch Office in Tokyo

Read more

argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018

Read more

TiGenix announces a change in its Board of Directors and its Management Team

Read more

Sanofi complets its acquisition of Ablynx following the expiration of the squeeze-out procedure

Read more

The first veterinary stem cell product recommended for approval in Europe becomes a reality

Read more

CMAST: Horizon Europe – looking at the future or building on the past?

Read more

Biogazelle appoints Armin Winands as new CEO

Read more

INNOVATION TRANSFORMING HEALTH CARE

Read more

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Read more

Xendo and its affiliate, Sofus Regulatory Affairs AB have been acquired by ProPharma Group

Read more

Novosanis obtains regulatory approval for Colli-Pee in Brazil

Read more

Promethera Biosciences Appoints Mutsuki Takano as General Manager of its Branch Office in Tokyo

Read more

MDxHealth: SelectMDx Study Demonstrates Cost-effectiveness in US Healthcare System

Read more

MDxHealth (R): MDxHealth Shareholder Transparency Declaration

Read more

GROWTH

Read more

Communicating Toxicology: What’s the Risk ?

Read more

Ardena expands nanomedicine capabilities

Read more

OPINNO

Read more

Mithra and Richter sign license and supply agreement for commercialization of Estelle®, a novel oral contraceptive

Read more

MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Read more

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Read more

Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of DME

Read more

argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million

Read more

Qarad nominated twice for TOPRA Awards

Read more

HR investment group Pyramid takes a stake in ORMIT

Read more

BioFIT 2018

Read more

Shareholder Transparency Declaration MDxHealth

Read more

Dutch Life Sciences conference

Read more

MDxHealth (R): SelectMDx improves prostate biopsy decision-making in urology practices

Read more

Novosanis Colli-Pee approved by Mexican health authority

Read more

Novalis: Seed capital for biotech, with link to big data and AI

Read more

MDxHealth Announces Approval for SelectMDx for Prostate Cancer by New York State

Read more

flanders.bio provides you with insights in the vibrant life sciences sector

Read more

flanders.bio offers a wide range of advantages and services to its members

Read more

Biocartis present at investor event VFB Happening this Saturday 25 March, Antwerp, BE

Read more

Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee

Read more

Belgian PCR interpretation software company UgenTec partners with multiplex molecular diagnostics innovator PathoFinder

Read more

Kiadis Pharma announces Annual Results for the year ended December 31, 2016

Read more

Biocartis Group NV: Biocartis establishes US subsidiary and appoints US General Manager

Read more

The Future of Health Technology: Lab on Chip & Diagnostics platform meeting

Read more

TiGenix reports 2016 full year results

Read more

2017 IIBN Forum - Biotechnology: from Innovation to Industrial Production

Read more

Bio-Based Live Europe : Creating sustainable products from bio-based innovations

Read more

Mithra Pharmaceuticals publie son rapport annuel 2016 et l’invitation à son Assemblée Générale Ordinaire des actionnaires

Read more

ThromboGenics Achieves Important Milestone in the Development of THR-149

Read more

Genohm releases the new version v5.4 of SLims

Read more

Esperite N.V. with CryoSave contributes to treating a 9 year old child with thalassema major in Switzerland

Read more

Flanders @ BIOJapan 2017: Flemish Life Sciences & Biotech Week

Read more

MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx

Read more

ThromboGenics NV : New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

Read more

Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

Read more

MDxHealth Trading Update: January to April 2017

Read more

Bone Therapeutics Business Update for First Quarter 2017

Read more

ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE

Read more

ThromboGenics Business Update - Q1 2017

Read more

Biocartis Group NV: Results of the annual shareholders' meeting held on 12 May 2017

Read more

argenx announces size of initial public offering in the United States increased to 5 million ADSs

Read more

Helena Biosciences to develop automated blood test for chronic liver disease based on VIB and Ghent University research

Read more

SLims by Genohm integrated with Pathomation’s PMA.core

Read more

Biocartis Group NV: Study demonstrating high performance of Idylla(TM) liquid biopsy RAS tests to be presented at ASCO Annual Meeting

Read more

argenx raises approximately $100 million gross proceeds with NASDAQ IPO

Read more

ThromboGenics NV to present THR-317 Pre-clinical Research Findings

Read more

argenx announces closing of NASDAQ IPO

Read more

Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®

Read more

Mithra Receives Orphan Drug Designation from EMA for E4 in Neonatal Encephalopathy

Read more

Belgium showcases expertise on Immunotherapy at the world’s largest Biotechnology Conference – San Diego, June 19- 23, 2017

Read more

Mithra Launches a Capital Increase by Means of a Private Placement via an Accelerated Bookbuild Offering

Read more

Lack of Knowledge on Clinical Advances Achieved by New Generation of Biomarker Tests for Prostate Cancer

Read more

Membership Information

Read more

BioInvent and ThromboGenics Amending Long-Standing Monoclonal Antibody Development Agreement

Read more

Delphi Genetics receives GMP accreditation for plasmid DNA bioproduction

Read more

Ablynx proposes appointment of Mrs. Hilde Windels as a new independent director

Read more

MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test

Read more

MDxHealth Appoints Seasoned EVP to Lead Sales Force Expansion

Read more

Interreg 2 Seas Project DERMA Industrial Matchmaking and Showcase Event

Read more

New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston

Read more

Mithra Announces First Subject Completes Estelle® Phase III Study

Read more

Bone Therapeutics Notice of Half Year 2017 Results

Read more

Ablynx announces 2017 half year results and year-to-date business update

Read more

SuperBIO close to reaching its goal of developing 30 cross-border, cross-sectorial value chains in the biobased economy

Read more

Genohm releases new SLIMS overview video

Read more

Bone Therapeutics announces H1 results for 2017

Read more

MDxHealth Announces First Half 2017 Financial Results

Read more

Biocartis Group NV: Biocartis announces 2017 half-year results on 7 September 2017

Read more

TiGenix obtains commercial production license for expanded manufacturing facility

Read more

MDxHealth Prepares for Growth with Executive Team Expansion

Read more

Biocartis Group NV: Results of the extraordinary shareholders' meeting held on 11 September 2017

Read more

Presentation of the results of flanders.bio's annual (Bio)Pharma Salary Survey

Read more

R-Biopharm AG & UgenTec partner to develop software for automated PCR analysis

Read more

Galapagos werft aan

Read more

Trainings - CONNECT / EDUCATE

Read more

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis

Read more

Daily Newsflash- 26/09/2017

Read more

ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting

Read more

ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US

Read more

Ablynx announces positive topline results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP

Read more

Key Considerations in Health Care Product Development

Read more

flanders.bio joins forces with FIT to support the internationalisation of Flanders’ economy

Read more

Participation by Capricorn Venture Partners completes ViroVet’s series A funding

Read more

Press Release - Life Sciences & Biotechnology

Read more

TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting

Read more

ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR

Read more

ESPERITE (ESP) : EUR 1.1 million of new funding provided by L1 Capital

Read more

Pauwels Consulting acquires Akros Solutions

Read more

Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017

Read more

Mithra Announces Launch of Warrant Exercise Period

Read more

Ionis Pharmaceuticals licenses novel antisense drug for the treatment of centronuclear myopathy to dynacure

Read more

For the second year in a row ProDigest wins the Life Science Technology Award in the Deloitte Technology Fast 50 Competition

Read more

Mindbytes initiates oncology R&D program focused on patient empowerment and is selected as one of five finalists for Astellas Oncology C3 Prize®

Read more

Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany

Read more

Mithra Confirms Conversion of Subscription Rights

Read more

Fast Track Diagnostics and UgenTec announce new interpretation software for all FTD real-time PCR multiplex kits

Read more

Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy (NPDR) Discontinued due to Slow Recruitment Rate

Read more

reMYND enters into license agreement with Novo Nordisk

Read more

BIO World Congress on Industrial Biotechnology

Read more

Mithra Announces Injectables Agreement with GSP

Read more

Bone Therapeutics Provides Update on Equity Placement

Read more

Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound

Read more

MDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients

Read more

Bone Therapeutics provides business outlook and announces its financial calendar for 2018

Read more

Mithra Announces Last Subject Completes Donesta® Phase II Study

Read more

Mithra announces very promising hemostasis results for Estelle®

Read more

new England biolabs® and Bluebee partner to deliver an end-to-end data analysis solution for Nebnext direct® target enrichment

Read more

MDxHealth Notice of Financial Year 2017 Results

Read more

European Union provides Biocartis with up to EUR 24m debt financing facility for infectious disease projects

Read more

Biocartis Establishes R&D Center in the US

Read more

Mithra Reports 2017 Annual Results

Read more

Mithra presents positive hemostasis results at ISGE conference

Read more

CTLS2018@VIB

Read more

Biocartis Selected for Oral Presentation at Cancer Research Meeting

Read more

MDxHealth (R): SelectMDx Liquid Biopsy Test for Prostate Cancer included in the 2018 European Association Urology Guidelines

Read more

Mithra Announces Completion of Estelle® Cycles Required in Phase III Contraception Studies

Read more

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

Read more

ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes

Read more

Biocartis Group NV: Biocartis announces publication of its 2017 annual report

Read more

ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data

Read more

Hamilton Robotics first company to join the UgenTec’s new Molecular Automation Network

Read more

Mithra releases 2017 Annual Report and invitation to its Ordinary General Shareholders' Meeting

Read more

Bone Therapeutics Notice of Full Year 2017 Results

Read more

ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

Read more

Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

Read more

Bone Therapeutics: preliminary documents for the Annual Ordinary and the Extraordinary General Shareholder Meeting

Read more

Biocartis: Results of the annual shareholders' meeting held on 11 May 2018

Read more

Press Release - Life Sciences & Biotechnology - 15/05/2018

Read more

Mithra announces injectable contract with Midas Pharma

Read more

Biocartis: Two Performance Studies on Idylla(TM) MSI Biomarkers Selected for Publication at ASCO Conference

Read more

Biocartis Group NV: Study Demonstrates Ability of Idylla(TM) EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

Read more

Mithra: information on the total number of voting rights

Read more

Daily newsflash - 06/06/2048

Read more

Mithra Announces Presentation of Donesta® Results at the International Menopause Society’s 16th World Congress

Read more

Bone Therapeutics announces results of Annual General Meeting

Read more

Thank you for attending the latest flanders.bio - Roche Diagnostics Partner Day

Read more

Biocartis Group NV: Study Reviewing 2,500 Performed Idylla(TM) Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods

Read more

MDxHealth's SelectMDx Test Successfully Stratifies Men

Read more

Internationalisation 24/09/2018 - 26/09/2018

Read more

Single-Use Event 2018: Bioprocessing in the future: Single Use and Continuous

Read more

Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix

Read more

ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study

Read more

Press Release - Life Sciences & Biotechnology - 26/07/2018

Read more

EIT Health Investor Forum

Read more

Biocartis Group NV: Study Abstract on Performance of Idylla(TM) RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US)

Read more

Bone Therapeutics Notice of Half Year 2018 Results

Read more

Mithra announces positive top-line results of estelle® phase III oral contraceptive study in eu/russia

Read more

argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody

Read more

Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response

Read more

Bioprocessing in the future: Single-Use and Continuous

Read more

GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT

Read more

Industry Insiders on the Future of Biopharma/Biotech in Belgium

Read more

Flanders @ BIOJapan 2018: Flemish Life Sciences & Biotech Week

Read more

Gilead and Galapagos announce filgotinib meets primary and all key secondary endpoints in first phase 3 study in rheumatoid arthritis

Read more

Mithra announces further details regarding contract gedeon richter

Read more

Bone Therapeutics to present at 26th Annual Meeting of the European Orthopaedic Research Society

Read more

PharmaFluidics Facilitates Ultra-high-resolution Proteomics Analysis Through Agreement with Thermo Fisher Scientific

Read more

UgenTec to extend its software portfolio with FastTyper, a platform used for high-throughput SNP genotyping by end-point PCR

Read more

Presentation of Donesta® PHIIB results at the 2018 annual meeting of the North American menopause society

Read more

flanders.bio - NBN event: Standards for Biotech

Read more

BIO Investor Forum

Read more

Biocartis Group NV: Studies on Idylla(TM) MSI and RAS liquid biopsy tests to be presented at ESMO congress

Read more

Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer

Read more

ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes

Read more

Why Ya Buggin’ Out? Regulatory Hurdles and Other Obstacles on the Path to Microbiome Market

Read more

Mithra reduces environmental impact of CDMO facility in Belgium with the installation of 1800 solar panels

Read more

Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results

Read more

Mithra Announces Positive Results of Ovarian Function Sub-Study which Strengthens Estelle® Contraceptive Efficacy Profile

Read more

Oxurion NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of New Website

Read more

Galapagos announces ISABELA Phase 3 program in IPF

Read more

Convert Pharmaceuticals appoints Mariola Söhngen as new CEO

Read more

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €296.2 million

Read more

Ablynx announces full exercise of underwriters' option to purchase additional shares and end of stabilization period

Read more

argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering

Read more

Galapagos raises $300 million gross proceeds in a U.S. public offering

Read more

Ablynx prices $200 million Initial Public Offering in the United States

Read more

argenx announces launch of proposed public offering in the United States

Read more

Takeda rondt overname van TiGenix af na het verstrijken van de Uitkoopperiode

Read more

MDxHealth and Queensland University of Technology Collaborate on Oral Cancer Liquid Biopsy Test

Read more

flanders.bio - Roche Diagnostics Partner Day 2018: ’Towards high-quality Cell Therapy’

Read more

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Read more

Galapagos raises $338 million gross proceeds in a U.S. public offering

Read more

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million

Read more

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Read more

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Read more